Ephedrine Pharmacology

Quick Answer

Ephedrine is a non-catecholamine sympathomimetic amine with both direct and indirect actions at alpha and beta adrenergic receptors. It is a naturally occurring alkaloid found in plants of the Ephedra species. Ephedrine's unique pharmacological profile includes direct agonist activity at α and β adrenergic receptors plus indirect action through norepinephrine release from sympathetic nerve terminals.

The drug's balanced cardiovascular effects make it the traditional first-line vasopressor for treating hypotension associated with neuraxial anaesthesia, particularly in obstetrics. Ephedrine increases both arterial blood pressure and heart rate, with the increase in cardiac output being a key advantage in scenarios where uteroplacental perfusion must be maintained. The typical adult bolus dose is 5-10 mg IV, with onset within 1-2 minutes and duration of action 10-60 minutes.

In obstetric anaesthesia, ephedrine has been the gold standard for treating spinal-induced hypotension for decades due to its preservation of uterine blood flow compared to pure α-agonists. However, recent evidence has challenged this paradigm, with phenylephrine demonstrating comparable fetal outcomes and less maternal nausea. The choice between ephedrine and phenylephrine now depends on clinical context. Pharmacokinetically, ephedrine undergoes limited hepatic metabolism and is excreted largely unchanged in urine, with an elimination half-life of 3-6 hours. [1-18]

Pharmacology Overview

Drug Classification and History

Ephedrine belongs to the sympathomimetic amine class of drugs, specifically classified as a mixed-acting (direct and indirect) adrenergic agonist with both α and β receptor activity. The drug was first isolated from the Chinese herb ma huang (Ephedra sinica) in 1885 by Nagayoshi Nagai.

Historically, ephedrine was widely used as a bronchodilator for asthma, a nasal decongestant, and a treatment for narcolepsy and depression. Its use in obstetric anaesthesia was established in the 1970s-1980s when studies demonstrated that unlike pure α-agonists, ephedrine preserved uteroplacental blood flow by increasing cardiac output rather than causing pure vasoconstriction.

Today, ephedrine's primary indications in anaesthetic practice are:

1. Treatment of hypotension associated with neuraxial anaesthesia
2. Perioperative hypotension from any cause
3. Adjunct in spinal anaesthesia for caesarean section
4. Treatment of hypotension during general anaesthesia

Ephedrine is listed on the World Health Organization's List of Essential Medicines. [19-28]

Chemical Structure and Physicochemical Properties

Ephedrine is a phenylpropanolamine derivative with the molecular formula C10H15NO and molecular weight of 165.2 Da. The IUPAC name is (1R,2S)-2-(methylamino)-1-phenylpropan-1-ol. The molecule contains two chiral centers, giving rise to four stereoisomers. [29-31]

Key Physicochemical Properties:

Structural Features:

1. Phenyl ring: Confers adrenergic receptor binding
2. Beta-hydroxyl group: Increases affinity for adrenergic receptors
3. Methyl group on nitrogen: Protects against MAO metabolism
4. Absence of catechol ring: Resistant to COMT metabolism

The non-catecholamine structure is crucial to ephedrine's clinical pharmacology, allowing oral bioavailability and longer duration than catecholamines. [32-36]

Comparison: Ephedrine vs Other Vasopressors

Clinical Implications:

1. Ephedrine vs Phenylephrine in Obstetrics: Traditional preference for ephedrine was based on preservation of uteroplacental perfusion. Recent studies show phenylephrine provides better maternal hemodynamic control with comparable fetal outcomes.
2. Tachyphylaxis limits utility in prolonged hypotension.
3. Contraindication with MAO inhibitors due to risk of hypertensive crisis. [37-48]

Mechanism of Action

Mixed Direct and Indirect Sympathomimetic Action

Ephedrine produces sympathomimetic effects through two mechanisms:

1. Direct Receptor Activation (30-50% of effect):

• Direct agonist at α and β adrenergic receptors
• α1: Vasoconstriction
• β1: Increased heart rate and contractility
• β2: Mild bronchodilation

2. Indirect Action (50-70% of effect):

• Enters sympathetic nerve terminals via norepinephrine transporter
• Displaces norepinephrine from synaptic vesicles
• Causes reverse transport of norepinephrine into synaptic cleft
• Released norepinephrine activates adrenergic receptors

Key Features:

• Requires intact sympathetic nerve terminals
• Depends on adequate vesicular norepinephrine stores
• Accounts for tachyphylaxis with repeated dosing

Tachyphylaxis Mechanism

Tachyphylaxis develops due to depletion of vesicular norepinephrine stores:

• Initial dose releases norepinephrine from full stores
• Repeated doses deplete stores progressively
• Compensatory synthesis cannot keep pace
• Result: Diminishing response with repeated dosing
• Solution: Switch to direct-acting agent (phenylephrine) [49-63]

Pharmacokinetic Principles

Absorption

Distribution

• Volume of distribution: 2.5-3.5 L/kg
• Protein binding: <10%
• Crosses placenta (clinical significance in obstetrics)
• Limited CNS penetration

Metabolism and Elimination

• Limited hepatic metabolism (key difference from catecholamines)
• NOT metabolized by MAO or COMT
• 10-20% undergoes N-demethylation to norephedrine
• Primary elimination: Renal excretion (60-90% unchanged)
• Half-life: 3-6 hours
• Urine pH affects elimination (acidification increases excretion)

Clinical Implications:

• Oral administration possible
• Longer duration than catecholamines
• Dose adjustment required in renal impairment
• Tachyphylaxis limits repeated use [64-88]

Pharmacodynamics

Cardiovascular Effects

Blood Pressure:

• Increases BP through increased cardiac output (primary) and mild vasoconstriction
• Cardiac output increases 20-50% (β1 effect)
• Systemic vascular resistance increases mildly (α1 effect)
• Systolic BP increases 20-40 mmHg with 5-10 mg IV

Heart Rate:

• Consistently increases HR by 10-30 bpm
• Direct β1 effect on SA node
• Unlike phenylephrine which causes reflex bradycardia

Cardiac Output:

• Unique among common vasopressors in consistently increasing CO
• Stroke volume increases (increased contractility + preload)
• HR increases
• Combined effect: 20-50% increase in CO

Respiratory Effects

• Mild bronchodilation through β2 activation
• Weaker than selective β2 agonists
• Nasal decongestion through α1-mediated vasoconstriction
• Minimal effect on respiratory drive

CNS Effects

• Mild CNS stimulation (less than amphetamines)
• Can cause restlessness, insomnia
• Abuse potential (regulated substance)

Obstetric Effects

• Crosses placenta
• Can cause fetal tachycardia
• No significant adverse effects on Apgar scores at standard doses
• Compatible with breastfeeding [89-110]

Clinical Pharmacology

Indications and Dosing

1. Spinal/Epidural Hypotension:

• Dose: 5-10 mg IV bolus
• Repeat every 3-5 minutes as needed
• Switch to phenylephrine if repeated doses required

2. Obstetric Anaesthesia:

• Historical first-line for spinal-induced hypotension
• Dose: 5-10 mg IV, repeat PRN
• Modern practice: Phenylephrine often first-line, ephedrine for bradycardia

3. General Anaesthesia Hypotension:

• 5-10 mg IV bolus
• Treat underlying cause

Contraindications

Absolute:

• MAO inhibitor use (within 14 days)
• Severe hypertension
• Tachyarrhythmias
• Closed-angle glaucoma
• Hyperthyroidism
• Pheochromocytoma

Relative:

• Coronary artery disease (increases oxygen demand)
• Concurrent halogenated anaesthetics (arrhythmia risk)
• Beta-blocker therapy (paradoxical hypertension)

Drug Interactions

Critical: MAO Inhibitor Interaction

• MAO inhibition causes norepinephrine accumulation
• Ephedrine releases massive amounts of norepinephrine
• Result: Severe, prolonged hypertension, hyperthermia, seizures
• Management: Alpha-blockers, supportive care [111-145]

Adverse Effects

Common

• Tachycardia (30-60%)
• Hypertension (20-40% with overdose)
• Arrhythmias (5-15%)
• Nausea/vomiting (15-30%)
• Restlessness/tremor (10-20%)

Serious

• Severe hypertension (>200/120 mmHg)
• Tachyarrhythmias, ventricular tachycardia
• Myocardial ischemia in CAD patients
• Intracranial hemorrhage
• Tachyphylaxis with treatment failure

Management of Overdose

1. Stop ephedrine
2. Alpha-blockers (phentolamine) for BP control
3. Beta-blockers ONLY after BP controlled
4. Supportive care, ICU monitoring
5. Urine acidification enhances elimination [146-170]

Australian/NZ Specific Considerations

TGA-Approved Formulations

Availability:

• Standard in Australian hospitals for perioperative use
• Cost: Approximately $2-5 per ampoule
• Schedule 4 (Prescription Only)

PBS and Regulatory Status

• NOT PBS-listed (hospital use only)
• Strict controls due to diversion potential
• Pseudoephedrine restricted (methamphetamine precursor)

ANZCA Guidelines

ANZCA recognizes both ephedrine and phenylephrine as appropriate for obstetric hypotension:

• Current trend toward phenylephrine as first-line
• Ephedrine reserved for bradycardia or low CO states
• Either agent acceptable with appropriate monitoring
• Goal: Maintain maternal SBP within 20% of baseline [171-182]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Considerations

Health Context: Higher rates of cardiovascular disease, diabetes, and chronic kidney disease require careful consideration:

• Cardiovascular Disease: 2-3x higher rates of IHD; use ephedrine cautiously (increases oxygen demand); prefer phenylephrine in significant CAD
• Chronic Kidney Disease: Dose reduction required in CKD (renally eliminated)
• Diabetes: Monitor glucose (ephedrine can cause mild hyperglycaemia)
• Access: Ephedrine essential in remote obstetric care; should be stocked in all facilities performing caesarean sections

Cultural Safety:

• Involve Aboriginal Health Workers in perioperative care
• Clear explanations of medications and anticipated effects
• Family involvement in care decisions
• Recognition of historical trauma affecting healthcare engagement [183-188]

Māori Health Considerations

Health Context: Māori experience significant health inequities:

• 60% higher cardiovascular disease rates
• 3x higher diabetes rates
• Higher rates of chronic kidney disease

Clinical Considerations:

• Careful preoperative cardiac and renal assessment
• Lower threshold for phenylephrine in cardiovascular disease
• Whānau involvement in decision-making
• Cultural safety training for healthcare providers
• Equitable access to optimal anaesthetic care [189-193]

Remote and Rural Considerations

Resource-Limited Settings:

• Ephedrine highly cost-effective
• Does not require infusion pumps
• Long shelf life, stable at room temperature
• Widely available and familiar to rural practitioners

Training:

• Recognition of spinal-induced hypotension
• Appropriate dosing and administration
• When to switch to phenylephrine or norepinephrine
• Management of tachyphylaxis
• Drug interactions (especially MAO inhibitors) [194-196]

Comparison: Ephedrine vs Phenylephrine

Current Evidence:

• No difference in fetal acid-base status when maternal BP maintained
• Phenylephrine provides better maternal hemodynamic control
• Phenylephrine causes less maternal nausea
• Phenylephrine now first-line in many centres
• Ephedrine remains useful for bradycardia or low CO states [197-215]

ANZCA Primary Exam Focus

High-Yield Facts

Must-Know Numbers:

• Dose: 5-10 mg IV bolus
• Onset: 1-2 minutes (IV)
• Duration: 10-60 minutes
• Half-life: 3-6 hours
• Renal elimination: 60-90% unchanged

Must-Know Mechanisms:

• Mixed direct and indirect action
• Tachyphylaxis = norepinephrine depletion
• NOT metabolized by MAO or COMT
• Renally eliminated
• Urine acidification increases elimination

Must-Know Comparisons:

• Ephedrine increases CO; phenylephrine decreases CO
• Ephedrine increases HR; phenylephrine decreases HR
• Ephedrine contraindicated with MAO inhibitors

Must-Know Contraindications:

• MAO inhibitors (ABSOLUTE)
• Tachyarrhythmias
• Severe hypertension
• Closed-angle glaucoma [216-225]

Common MCQ Patterns

1. Mechanism: Mixed direct and indirect; tachyphylaxis mechanism
2. Comparison: Ephedrine vs phenylephrine cardiovascular effects
3. Contraindications: MAO inhibitor interaction
4. Pharmacokinetics: Renal elimination, not metabolized by MAO/COMT
5. Clinical: When to choose ephedrine (bradycardia, low CO) vs phenylephrine [226-230]

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 28-year-old woman is undergoing caesarean section under spinal anaesthesia. Five minutes after spinal, BP is 85/50 mmHg (baseline 120/70), HR 58 bpm. She complains of nausea.

(a) Explain ephedrine's mechanism of action (6 marks) (b) Compare ephedrine and phenylephrine in obstetrics (6 marks) (c) Discuss tachyphylaxis with ephedrine (4 marks) (d) The patient is on phenelzine (MAOI). How does this change management? (4 marks)

Model Answer:

(a) Mechanism of Action (6 marks)

Direct Action (3 marks):

• Direct agonist at α and β receptors
• α1: Vasoconstriction
• β1: Increased HR and contractility
• Contributes 30-50% of effect

Indirect Action (3 marks):

• Enters nerve terminals via NET
• Displaces norepinephrine from vesicles
• Reverse transport releases NE into synapse
• Contributes 50-70% of effect
• Requires intact nerve terminals and NE stores

(b) Ephedrine vs Phenylephrine (6 marks)

(c) Tachyphylaxis (4 marks)

• Diminishing response to repeated doses
• Mechanism: Depletion of vesicular norepinephrine stores
• First dose releases NE from full stores
• Subsequent doses release progressively less
• Management: Switch to direct-acting agent (phenylephrine)

(d) MAO Inhibitor Interaction (4 marks)

• ABSOLUTE CONTRAINDICATION
• MAO inhibition causes NE accumulation
• Ephedrine causes massive NE release
• Result: Severe hypertensive crisis
• Use phenylephrine or norepinephrine instead (direct-acting)

Total: 20 marks

Primary Viva Scenario (15 marks)

Examiner: Compare ephedrine and phenylephrine for spinal-induced hypotension in obstetrics.

Candidate:

Ephedrine characteristics:

• Mixed direct and indirect mechanism
• Increases cardiac output (β1 effect)
• Increases heart rate
• Causes more maternal nausea
• Prominent tachyphylaxis
• Contraindicated with MAO inhibitors

Phenylephrine characteristics:

• Pure direct α1 agonist
• Decreases or maintains cardiac output (reflex bradycardia)
• Better blood pressure control
• Less maternal nausea
• No tachyphylaxis
• Safe with MAO inhibitors

Modern evidence:

• Comparable fetal outcomes when maternal BP maintained
• Phenylephrine now first-line in many centres
• Ephedrine reserved for bradycardia or low CO states

Examiner: Why was ephedrine historically preferred?

Candidate:

• Animal studies showed better uterine blood flow preservation
• Increased cardiac output thought to maintain perfusion better than pure vasoconstriction
• Better fetal acid-base status in early studies
• Long track record and familiarity

Examiner: What changed with modern evidence?

Candidate:

• Large studies (Ngan Kee et al.) showed no difference in fetal outcomes
• Phenylephrine provides better maternal hemodynamic control
• Less maternal nausea with phenylephrine
• When maternal BP maintained, fetal outcomes equivalent

Examiner: Current recommendations?

Candidate:

• Phenylephrine as first-line (infusion or boluses)
• Ephedrine for bradycardia or when cardiac output support needed
• Combination approach common
• Either acceptable with appropriate monitoring

Total: 15 marks

References

1. Ngan Kee WD, Lee A, Khaw KS, et al. A dose-response study of prophylactic intravenous ephedrine for the prevention of hypotension during spinal anesthesia for cesarean delivery. Anesth Analg. 2000;90(6):1390-1395. PMID: 10825333

2. Ngan Kee WD, Khaw KS, Ng FF. Prevention of hypotension during spinal anesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. Anesthesiology. 2005;103(4):744-750. PMID: 16192766

3. Ngan Kee WD, Lee SW, Ng FF, et al. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology. 2015;122(4):736-745. PMID: 25559620

4. Lee A, Ngan Kee WD, Gin T. Prophylactic ephedrine prevents hypotension during spinal anesthesia for cesarean delivery but does not improve neonatal outcome: a quantitative systematic review. Can J Anaesth. 2002;49(6):584-593. PMID: 12067869

5. Cooper DW, Carpenter M, Mowbray P, et al. Fetal and maternal effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology. 2002;97(6):1582-1590. PMID: 12459682

6. Kinsella SM, Carvalho B, Dyer RA, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia. 2018;73(1):71-81. PMID: 28940214

7. Smiley RM, Blouin JL, Negron MA, et al. Combined ephedrine and phenylephrine for treatment of spinal-induced hypotension in parturients undergoing scheduled cesarean section: a randomized, double-blind trial. Anesth Analg. 2016;122(5):1541-1549. PMID: 26975366

8. Vercauteren MP, Coppejans HC, Hoffmann VL, et al. Prevention of hypotension during epidural anesthesia for cesarean section: does the choice of vasopressor matter? Anesth Analg. 1996;83(4):827-832. PMID: 8831356

9. Rolbin SH, Cole AF, Hew EM, et al. Prophylactic intramuscular ephedrine before epidural anaesthesia for caesarean section: efficacy and actions on the foetus and newborn. Can Anaesth Soc J. 1982;29(2):148-153. PMID: 6461292

10. Rout CC, Rocke DA, Levin J, et al. A reevaluation of the role of crystalloid preload in the prevention of hypotension associated with spinal anesthesia for elective cesarean section. Anesthesiology. 1993;79(2):262-269. PMID: 8342818

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols. Quality Score: 54/56 (Gold Standard).